family with sequence similarity 110 member CGenealiases: []
Q-omics provides the consensus-scored FAM110C profile across patient tissues and cancer cell-line models. FAM110C expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM110C is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, FAM110C RNA expression shows 17,350 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where FAM110C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM110C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM110C survival associations across molecular data types. FAM110C RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM110C RNA expression–survival associations across cancer types. High FAM110C expression shows unfavorable associations in HNSC, LUAD and LGG, but favorable associations in KIRC, COAD and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM110C RNA expression.
This table summarizes FAM110C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM110C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM110C shows lower tumor expression in KICH, LIHC and READ and higher tumor expression in THCA, KIRC and LUSC. The KICH box plot shows higher FAM110C RNA expression in normal versus tumor tissue (log2 FC = −4.570, t-test p < 0.001).
This table shows molecular features associated with FAM110C in patient tissues and cancer cell lines. In patient samples, FAM110C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM110C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
